Table 1.
Clinical features of women treated with UDCA based upon the ratio of Bacteriodetes to Firmicutes.
| High B:F (n = 7) Median (IQR) | Low or Parity B:F (n = 10) Median (IQR) | Comparison | |
|---|---|---|---|
| Maternal age (years) | 36 (34 to 40) | 35 (29 to 38) | ns |
| Gestation itch commenced (week+day) | 28+3 (21+0 to 29+0) | 32+4 (29+0 to 34+4) | ns |
| Gestation of sample (week+day) | 35+5 (30+5 to 36+5) | 36+5 (34+4 to 37+1) | ns |
| UDCA total dose prior to sample (g)* | 76 (15 to 92) | 10 (1 to 19) | p = 0.004 |
| Peak bile acid concentration pre-sample (µmol/L) | 65 (41 to 214) | 40 (26 to 75) | ns |
| Bile acid concentration at time of sample (µmol/L) | 46 (21 to 136) | 29 (19 to 50) | ns |
| Peak bile acid concentration throughout pregnancy (µmol/L) | 78 (64 to 254) | 60 (29 to 109) | ns |
B: Bacteroidetes; F: Firmicutes; n: number; IQR: interquartile range; ns: not significant. *Total UDCA dose assuming 100% compliance, calculated using prescribed dose(s) and duration. Comparisons using two-tailed student’s t-tests, p < 0.05 defined as threshold of significance.